Aims : to describe progress in non-pharmacological management of patients with fibrosing interstitial lung diseases (f-ILDs), including changes in clinical practice and the efficacy of treatments, using a patient-centred approach; to analyse the importance of self-management and the growing role of information and computing technologies in supporting monitoring, rehabilitation and non-pharmacological interventions in f-ILDs, including after lung transplantation; to describe non-pharmacological interventions that aim to relieve symptoms and improve quality of life; to provide an update on dedicated pulmonary rehabilitation strategies and outcome measures in f-ILDs, considering the "new normal" in the context of the pandemic; to discuss new insights into the role of oxygen supplementation in management of breathlessness and the role of ambulatory oxygen in preventing exertional hypoxaemia and maximising the benefits of pulmonary rehabilitation.